Evidence map›Paper›PMID 33731548›Full record

SynthesisJournal of clinical and experimental hematopathology : JCEH2021

Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A.

Tomohiro Kinoshita, Takashi Watanabe, Kuniaki Itoh, Kenichi Yoshimura, Kensei Tobinai, Michinori Ogura, Motoko Yamaguchi, Mitsutoshi Kurosawa, Yoshitaka Imaizumi, Shuichi Ota and 8 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of clinical and experimental hematopathology : JCEH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 2 countries.

Tomohiro KinoshitaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi WatanabeDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kuniaki ItohDivision of Oncology and Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
Kenichi YoshimuraDepartment of Biostatistics, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Michinori OguraDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Motoko YamaguchiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Mitsutoshi KurosawaDepartment of Hematology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan.
Yoshitaka ImaizumiNagasaki University Hospital, Nagasaki, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Harumi KabaData Management Division, Clinical Research Support Office, National Cancer Center, Tokyo, Japan.
Kiyoshi MukaiPathology Division, National Cancer Center Research Institute, Tokyo, Japan.
Shigeo NakamuraDepartment of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan.
Koichi OhshimaFirst Department of Pathology, Kurume University School of Medicine, Kurume, Japan.
Tomomitsu HottaDepartment of Hematology and Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Kunihiro TsukasakiDepartment of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan.
Hirokazu NagaiClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Masanori ShimoyamaNational Cancer Center Hospital, Tokyo, Japan.
Aichi Cancer Center · JPNational Cancer Center · USHiroshima University Hospital · JPJapan Clinical Cancer Research Organization · JPKurume University · JPMie University · JPNagasaki University Hospital · JPNagoya Medical Center · JPNagoya University Hospital · JPNational Cancer Center Hospital East · JPNational Hospital Organization · JPSaitama Medical University · JPSapporo Hokuyu Hospital · JPSapporo National Hospital · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central pathological review, 829 patients were diagnosed with BCL according to the World Health Organization classification and treated with doxorubicin-containing combination chemotherapies. Of these patients, 642, 104, 30, and 24 patients were diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL), respectively. The overall survival (OS) of FL and MZL patients was higher than that of patients with DLBCL and MCL. The OS of the MCL patients was higher than that of DLBCL patients in the first 5 years, but MCL had the lowest survival after 5 years. The OS of DLBCL patients was clearly stratified by the international prognostic index and showed data compatible with that of aggressive lymphoma in the pre-rituximab era. These results established the clinical aspects of BCL in a large number of patients treated in prospective studies during the pre-rituximab era in Japan.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsClinical Decision-MakingClinical Trials as TopicDisease ManagementDisease ProgressionFemaleHumansJapanLymphoma, B-CellMaleMiddle AgedMulticenter Studies as TopicNeoplasm GradingNeoplasm MetastasisNeoplasm Stagingaggressive lymphomaB-cell lymphomaclinical trialsdiffuse large B-cell lymphomainternational prognostic index

Identifiers

PMID33731548
PMCPMC8053572
OpenAlexW3137589491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.